FGF21 and metabolic dysfunction-associated steatotic liver disease: In conclusion, recombinant FGF21 attenuates PCB-induced NAFLD/NASH by modulating hepatic LCN2 expression, and hepatic LCN2 may represent a suitable therapeutic intervention target for PCB exposure-induced NAFLD/NASH.